Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilzabrutinib + glucocorticoids
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Rilzabrutinib + glucocorticoids** is a combination therapy studied for immune-mediated diseases such as IgG4-related disease and immune thrombocytopenia (ITP). Rilzabrutinib is an oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor that modulates immune responses by targeting BTK pathways. Glucocorticoids (such as prednisone) are synthetic corticosteroid hormones that suppress wide-ranging inflammatory and immune pathways via glucocorticoid receptor agonism. The combination aims to harness rilzabrutinib’s targeted B-cell modulation alongside the broad anti-inflammatory effects of glucocorticoids, which are standard-of-care in many autoimmune disorders. The combination has been studied in clinical trials, including a phase 2a trial in IgG4-related disease, showing potential for disease activity reduction and glucocorticoid-sparing effects[1][4][2].
- Brand names
- Wayrilz
- Other names
- rilzabrutinib + corticosteroids
02
Targets
TXKBLK (B lymphoid tyrosine kinase)BMX (Bone Marrow Tyrosine Kinase X-linked)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on rilzabrutinib + glucocorticoids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilzabrutinib + glucocorticoids.